Researchers in the Netherlands argued in Nature Medicine that whole-genome sequencing (WGS) should be incorporated into routine cancer care, proposing it can identify clinically actionable biomarkers broadly enough to justify use beyond targeted panel testing. In their real-world dataset from the Netherlands Cancer Institute in Amsterdam, WGS found actionable results in 73% of patients. The study reported clinically relevant WGS outcomes—including already-targeted biomarkers, pathogenic germline variants, and diagnostic clarification—in 41% of the 888 patients analyzed. The team used Illumina platforms at the Hartwig Medical Foundation and benchmarked WGS against commonly used next-generation sequencing panels, including Thermo Fisher’s 50-gene AmpliSeq Cancer Hotspot panel and Illumina’s TruSight Oncology 500. The authors’ argument centers on avoiding gaps created by piecemeal mutation-panel approaches, while also weighing WGS costs versus the aggregate expense of multiple assays. For clinicians and diagnostics developers, the actionable headline is the push toward WGS as a unifying test that could expand therapeutic matching, germline identification, and trial eligibility in routine workflows.